Morgan Stanley Downgrades Bristol-Myers Squibb Co. (BMY) to Equalweight
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/21/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- Tesla acquires AI hardware company for up to $2 billion in stock
Piper Jaffray Cuts Bristol-Myers (BMY) PT, Raises Merck's (MRK) Following BMY's CM-026 Failure
August 8, 2016 6:37 AM EDTPiper Jaffray analyst Richard Purkiss lowered his price target on Neutral-rated Bristol-Myers Squibb Co. (NYSE: BMY) to $65.00 (from $69.00) following news Friday that its CheckMate-026 (CM-026) trial of Opdivo missed its primary endpoint in the treatment of PD-L1+ expressors (>5% PD-L1+,~55-60% of patients) in... More
Bristol-Myers Squibb (BMY) Says CheckMate -026 Trial for Opdivo Missed Primary Endpoint
August 5, 2016 8:21 AM EDTBristol-Myers Squibb Company (NYSE: BMY) announced that CheckMate -026, a trial investigating the use of Opdivo (nivolumab) as monotherapy, did not meet its primary endpoint of progression-free survival in patients with previously untreated advanced non-small cell lung cancer (NSCLC) whose tumors expressed PD-L1 at 5%. The company will complete a full evaluation of the... More
